Forty Seven Overview

  • Founded

  • 2015

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 68

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $4.7B

  • Investors

  • 1

Forty Seven General Information

Description

Developer of immuno-oncology therapies to activate macrophages intended to fight cancer. The company engages in the development of therapies based on anti-CD47 which can be used as monotherapy or in combination with anti-cancer antibodies, checkpoint inhibitors and chemotherapy or small molecules, enabling patients with anti-CD47 and related immunotherapies to patients in need.

Contact Information

Website
www.fortyseveninc.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Gilead Sciences
Primary Office
  • 1490 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Forty Seven Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 07-Apr-2020 $4.7B 00000 00.00 Completed Generating Revenue/Not Profitable
8. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
7. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
6. PIPE 07-Aug-2019 000 Cancelled Clinical Trials - Phase 1
5. 2PO 01-Jul-2019 000.00 00000 Completed Generating Revenue
4. IPO 28-Jun-2018 00000 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 17-Oct-2017 0000 00000 00000 Completed Clinical Trials - Phase 1
2. Grant 05-Apr-2017 $4.2M $74.8M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 01-Mar-2016 $74.8M $74.8M 00000 Completed Startup
To view Forty Seven’s complete valuation and funding history, request access »

Forty Seven Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series A2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A1 34,400,000 $0.000100 8% $1 $1 1x $1 17.55%
To view Forty Seven’s complete cap table history, request access »

Forty Seven Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immuno-oncology therapies to activate macrophages intended to fight cancer. The company engages in the deve
Biotechnology
Menlo Park, CA
68 As of 2019
00000
0.00 0000-00-00
000000&0 00000

0000 0

ptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000000
Santa Monica, CA
000 As of 0000
00000
00.00 0000-00-00
000000&0 00000

000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000000000000
Cambridge, MA
00 As of 0000
00000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Forty Seven Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
0000000 Formerly VC-backed Cambridge, MA 00 00000 000000&0
0000000 0000000000 Formerly VC-backed Houston, TX 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 Formerly VC-backed Planegg, Germany 00 0000 000000000 0000
You’re viewing 5 of 48 competitors. Get the full list »

Forty Seven Patents

  • 112

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 7

    Pending

  • 000

    Expiring in next 12 mo

Forty Seven Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4132580-A1 Antibody formulation Pending 06-Apr-2020 00000000000
AU-2021251661-A1 Antibody formulation Pending 06-Apr-2020 00000000000
CA-3179162-A1 Antibody formulation Pending 06-Apr-2020 00000000000
US-20230081265-A1 Antibody formulation Pending 06-Apr-2020 00000000000
US-20210147568-A1 Anti-cd47 based treatment of blood cancer Pending 31-Oct-2019 C07K16/2803 0
To view Forty Seven’s complete patent history, request access »

Forty Seven Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Forty Seven Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blackstone Life Sciences PE/Buyout Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Leukemia & Lymphoma Society Not-For-Profit Venture Capital Minority 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Forty Seven Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 01-Jun-2018 000000000 Buildings and Property
To view Forty Seven’s complete investments history, request access »

Ready to get started?

Request a free trial